|(3S,5S)-Atorvastatin (sodium salt)
negetive control of Atorvastatin, HMG-CoA reductase inhibitor
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||1428118-38-0||SDF||Download SDF|
|Chemical Name||2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, monosodium salt|
|Canonical SMILES||O=C(C1=C(C(C)C)N(CC[[email protected]](O)C[[email protected]](O)CC([O-])=O)C(C2=CC=C(F)C=C2)=C1C3=CC=CC=C3)NC4=CC=CC=C4.[Na+]|
|Formula||C33H34FN2O5 • Na||M.Wt||580.6|
|Solubility||≤0.5mg/ml in ethanol;15mg/ml in DMSO;25mg/ml in dimethyl formamide||Storage||Store at -20°C|
|Physical Appearance||A crystalline solid||Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase . Atorvastatin is a synthetic HMG-CoA reductase inhibitor implicated in lowering plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. Atorvastatin also reduces triglyceride levels through an as yet unproven mechanism . In various trials in patients with hypercholesterolaemia, atorvastatin produced greater reductions in total cholesterol, apolipoprotein B, LDL-cholesterol and triglyceride levels. In patients with primary hypercholesterolaemia, atorvastatin in combination with colestipol produced significant reductions in LDL-cholesterol levels and smaller reductions in triglyceride levels than atorvastatin monotherapy .
 Kocarek T A, Dahn M S, Cai H, et al. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2002, 30(12): 1400-1405.
 Lea A P, McTavish D. Atorvastatin[J]. Drugs, 1997, 53(5): 828-847.